Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Benzamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.73 |
| ▸ | PARP1 | P09874 | 2/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | RECQL | P46063 | 1/20 | 0.73 |
| ▸ | BLM | P54132 | 1/20 | 0.73 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.73 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.50 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.50 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzamide SCHEMBL8312382 | 0.94 | TSHR (0.64) | TSHRHSD17B10PARP1POLBCYP3A4 | |
| Benzamide SCHEMBL4726018 | 0.91 | TSHR (0.67) | TSHRHSD17B10PARP1POLBCYP3A4 | |
| Benzamide SCHEMBL694831 | 0.90 | TSHR (0.64) | TSHRHSD17B10PARP1POLBCYP3A4 | |
| Benzamide SCHEMBL4198407 | 0.86 | TSHR (0.59) | TSHRHSD17B10PARP1POLBCYP3A4 | |
| Benzamide SCHEMBL16352 | 0.85 | — | — | |
| Benzamide SCHEMBL1222101 | 0.85 | PARP1 (1.00) | TSHRHSD17B10PARP1POLBCYP3A4 | |
| Benzamide SCHEMBL6690447 | 0.85 | PARP1 (1.00) | TSHRHSD17B10PARP1POLBCYP3A4 | |
| Benzamide SCHEMBL1332331 | 0.85 | — | — | |
| SCHEMBL21755166 | 0.85 | PARP1 (1.00) | TSHRHSD17B10PARP1POLBCYP3A4 | |
| Benzamide SCHEMBL30112947 | 0.85 | PARP1 (1.00) | TSHRHSD17B10PARP1POLBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110511173-A | A kind of indolyl piperazine benzamide compound and its application | UNIV FUDAN | 2019-11-29 | — | — | CN | claimed |
| CN-111377846-B | Piperazine benzamide derivative and application thereof | 江苏恩华药业股份有限公司 | 2022-05-24 | — | — | CN | disclosed |
| CN-111377846-B | Piperazine benzamide derivative and application thereof | 江苏恩华药业股份有限公司 | 2022-05-24 | — | — | CN | disclosed |
| CN-111377846-A | Piperazine benzamide derivative and application thereof | 江苏恩华药业股份有限公司 | 2020-07-07 | — | — | CN | disclosed |
| CN-111377846-A | Piperazine benzamide derivative and application thereof | 江苏恩华药业股份有限公司 | 2020-07-07 | — | — | CN | disclosed |
| CN-110511173-A | A kind of indolyl piperazine benzamide compound and its application | UNIV FUDAN | 2019-11-29 | — | — | CN | disclosed |
| CN-110511173-A | A kind of indolyl piperazine benzamide compound and its application | UNIV FUDAN | 2019-11-29 | — | — | CN | disclosed |
| CN-105050623-B | Combination of PI3K inhibitor and C-MET inhibitor | 诺华股份有限公司 | 2018-06-12 | — | — | CN | disclosed |
| EP-2978763-B1 | 2-KETO AMIDE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2018-03-07 | — | — | EP | disclosed |
| EP-2975038-B1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK(NO 4) LTD (GB) | 2017-07-12 | — | — | EP | disclosed |
| WO-2004035541-A1 | BENZYL SUBSTITUTED (PIPERIDIN-4-YL) AMINOBENZAMIDO DERIVATIVES AS DELTA-OPIOD RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-04-29 | — | — | WO | disclosed |
| US-20040082612-A1 | Benzyl substituted (piperidin-4-yl)aminobenzamido derivatives | JANSSEN PHARMACEUTICALS N.V. (BE) | 2004-04-29 | — | — | US | disclosed |
| US-20040063744-A1 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2004-04-01 | — | — | US | disclosed |
| US-20040063746-A1 | Indole, azaindole and related heterocyclic ureido and thioureido piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2004014380-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
| EP-1389189-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION (US) | 2004-02-18 | — | — | EP | disclosed |
| WO-2004011425-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC UREIDO AND THIOUREIDO PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-05 | — | — | WO | disclosed |
| US-20040006090-A1 | Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2004-01-08 | — | — | US | disclosed |
| WO-2004000210-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC SULFONYLUREIDO PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-31 | — | — | WO | disclosed |
| WO-2002094799-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063744-A1 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | IDO1, IDO2, INMT | TSHR 4331/4885HSD17B10 3261/4885PARP1 76/4885 |
| US-20040006090-A1 | Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives | IDO1, IDO2, INMT | TSHR 2792/4885HSD17B10 3192/4885PARP1 263/4885 |
| US-20040082612-A1 | Benzyl substituted (piperidin-4-yl)aminobenzamido derivatives | OPRD1, OPRK1, OPRM1 | TSHR 625/4885HSD17B10 3703/4885PARP1 2731/4885 |
| US-20040063746-A1 | Indole, azaindole and related heterocyclic ureido and thioureido piperazine derivatives | IDO1, IDO2, TPMT | TSHR 1909/4885HSD17B10 3642/4885PARP1 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.